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Kidney failure after treatment 
with 90Y-DOTATOC
Dear Sir,
We read with interest the case report of Cybulla and co-
workers [1] and the comprehensive editorial comment
[2] on a case of kidney failure after 90Y-DOTATOC ther-
apy, and strongly feel that some comments and clarifica-
tion are needed. Certainly, tumour therapy often – if not
always – appears to be like sailing between Scylla and
Charybdis. Complete tumour remissions would most of-
ten be achieved with a number of therapeutic agents if
the dose-dependent side-effects could be neglected. The
knowledge of tubular re-absorption of peptides and, thus,
potential radiation-induced kidney toxicity in radiopep-
tide therapy is not new. The Basel experience began in
1996, when the first patients were treated with 90Y-
DOTATOC. Initial results regarding tumour response
and symptomatic relief were promising, but it became
evident that kidney protection was necessary [3]. From
multiple studies it is known that an amino acid solution
is able to reduce renal tubular uptake of labelled peptides
or antibodies [4, 5, 6, 7]. Since the middle of 1998, each
patient treated in Basel has received a Hartmann-Hepa
8% solution [Ringer-Lactate Hartmann (500 ml), Pro-
teinsteril Hepa 8% (1,500 ml), and Mg 5-Sulfat 10%
(30 ml)] for kidney protection, beginning 30 min before
the therapeutic injection and in each 90Y-DOTATOC
treatment session.
The patient to whom Cybulla et al. [1] refer was treat-
ed in the transitional period; unfortunately she received
kidney protection only in the last of the four treatment
sessions. An important detail in the history of this patient
was not mentioned by the authors or escaped their
notice: she suffered from bilateral hydronephrosis after
recurrent urinary tract infections prior to the 90Y-
DOTATOC treatment. The fate of this particular patient
is known in detail to us, and was an essential part of two
earlier publications from this hospital [3, 8]. The publi-
cation by Moll et al. [8], which surprisingly is not quoted
in the case report, deals exclusively with the topic of
renal thrombotic microangiopathy following 90Y-
DOTATOC treatment; this indicates the high importance
given to the issue in our department. The report of
Cybulla et al. [1] is thus the third publication to deal
with this patient in particular.
During long-term follow-up of up to 5 years in nearly
400 patients, renal insufficiency after 90Y-DOTATOC
therapy has not appeared frequently. It is conceivable
that there might be a correlation between the develop-
ment of renal failure after 90Y-DOTATOC treatment and
tumour mass, the somatostatin receptor density of the tu-
mour, the health status of the patient, prior chemotherapy
(especially with carboplatin and methotrexate), external
beam irradiation or other forms of internal radiotherapy
(e.g. radioiodine). A publication on long-term efficacy
and safety data is in internal revision.
Decision making in desperate situations of progres-
sive disease is always like sailing between Scylla and
Charybdis, the potential benefit of treatment being
weighed against the generally low risk of a potentially
harmful side-effect. The decision on the use of 90Y-
DOTATOC therapy has to be reached in discussions be-
tween the patient, the referring physician and the nuclear
medicine department.
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